Revenue and Profitability - The company's revenue for Q1 2025 was ¥139,216,213.10, representing a 13.90% increase compared to ¥122,227,974.51 in the same period last year[6] - Net profit attributable to shareholders decreased by 69.50% to ¥1,082,077.92 from ¥3,547,307.04 year-on-year[6] - The net profit for the period was a loss of ¥762,780.33, contrasting with a profit of ¥2,893,085.07 in the previous period[20] - The weighted average return on equity decreased to 0.12% from 0.37% year-on-year, reflecting a decline in profitability[6] - The company reported a basic earnings per share of ¥0.01, down from ¥0.03 in the previous period[20] Cash Flow - The net cash flow from operating activities was negative at -¥28,774,281.53, worsening by 18.79% compared to -¥24,222,072.61 in the previous year[6] - Cash flow from operating activities showed a net outflow of ¥28,774,281.53, compared to a net outflow of ¥24,222,072.61 in the previous period[21] - The cash inflow from operating activities totaled ¥107,168,250.73, down from ¥157,223,568.99 in the previous period[21] - Net cash flow from investing activities was -¥82,126,429.98, a decrease of 41.28% compared to Q1 2023, primarily due to increased cash payments for fixed assets[13] - Net cash flow from financing activities for Q1 2024 is 96,023,008.50 yuan, an increase of 112.04% compared to Q1 2023, mainly due to increased bank borrowings[13] Assets and Liabilities - Total assets grew by 4.43% to ¥2,913,552,562.84 from ¥2,789,880,328.86 at the end of the previous year[6] - Total current assets as of March 31, 2025, amount to 872,425,299.25 yuan, up from 769,997,377.12 yuan at the beginning of the period[17] - Total liabilities increased to ¥1,901,488,230.91 from ¥1,775,238,273.87, representing a growth of 7.1%[18] - The total liabilities include short-term borrowings of 291,238,917.77 yuan, slightly down from 294,303,069.17 yuan[17] - The total equity decreased slightly to ¥1,012,064,331.93 from ¥1,014,642,054.99, a decline of 0.3%[18] Research and Development - R&D expenses increased by 46.20% to ¥13,895,986.99 from ¥9,505,034.39 year-on-year, primarily due to new R&D activities by subsidiary Huahai[11] - Research and development expenses increased significantly to ¥13,895,986.99, compared to ¥9,505,034.39, marking a growth of 46.5%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,915, with no preferred shareholders having restored voting rights[12] - The largest shareholder, Xi Zubin, holds 31.72% of shares, totaling 36,567,000 shares, with 27,425,250 shares under lock-up[12] - The company has a total of 38,614,444 shares under lock-up, with no shares released during the reporting period[15] Financial Expenses and Losses - The financial expenses surged by 259.48% to ¥10,371,045.89, mainly due to the cessation of capitalization of project loans and convertible bond interest[11] - The company incurred financial expenses of ¥10,371,045.89, significantly higher than ¥2,885,024.73 in the previous period, indicating an increase of 260.5%[20] - The company recorded a loss from asset disposal of ¥1,572,500.23, attributed to the disposal of fixed assets during the period[11] Other Financial Metrics - The company reported a significant increase in prepayments by 67.03% to ¥17,908,414.10, indicating higher advance payments for goods[9] - The cash and cash equivalents at the end of the reporting period amount to 157,140,791.92 yuan, an increase from 141,181,205.23 yuan[16] - The ending cash and cash equivalents balance was $85.30 million, an increase from $59.43 million year-over-year[22] - Cash outflow for debt repayment was $33.02 million, down from $38.62 million, indicating reduced debt servicing costs[22] - Cash paid for dividends and interest was $2.90 million, slightly down from $3.09 million, reflecting stable shareholder returns[22] Accounting and Reporting - The first quarter report was not audited, which may affect the reliability of the financial data presented[23] - The company will implement new accounting standards starting in 2025, which may impact future financial reporting[24]
共同药业(300966) - 2025 Q1 - 季度财报